Respiratory Disease News and Research RSS Feed - Respiratory Disease News and Research

Green vegetation near homes plays important role in reducing mortality

Green vegetation near homes plays important role in reducing mortality

Women live longer in areas with more green vegetation, according to new research funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. Women with the highest levels of vegetation, or greenness, near their homes had a 12 percent lower death rate compared to women with the lowest levels of vegetation near their homes. The results were published Apr. 14, 2016 in the journal Environmental Health Perspectives. [More]
Cigarette smoking, viral infections may reduce effectiveness of COPD symptom-reliever medication

Cigarette smoking, viral infections may reduce effectiveness of COPD symptom-reliever medication

New study backs up observations in Chronic Obstructive Pulmonary Disease (COPD) patients showing reduced effectiveness of symptom-reliever medication (β2-adrenoceptor agonists) in flare-ups linked to cigarette smoking and infection with viruses such as influenza. [More]
Study finds evidence of lung function abnormalities in light-use hookah smokers

Study finds evidence of lung function abnormalities in light-use hookah smokers

A study of light-use hookah or waterpipe smokers found evidence of lung function abnormalities, including marked changes in cells lining the airways. The study, "Pulmonary Abnormalities in Young, Light-use Waterpipe (Hookah) Smokers," was published recently in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
N-KICS tool helps describe intensity of nursing care for children with CMC

N-KICS tool helps describe intensity of nursing care for children with CMC

Recent medical advances have resulted in increased survival of children with complex medical conditions (CMC), such as cerebral palsy, complex chromosomal anomalies, major congenital heart diseases and respiratory disease. [More]
Teach-to-goal inhaler education improves mastery of life-saving technique

Teach-to-goal inhaler education improves mastery of life-saving technique

A rescue inhaler can be a lifesaver during an asthma or COPD flareup, but using a rescue inhaler is complicated and misuse is common, putting patients' lives at risk. An education strategy, called teach-to-goal, may help patients use their inhalers properly during these critical times, according to research published online ahead of print in the American Thoracic Society journal Annals of the American Thoracic Society. [More]
Public health benefits of using more recycled water

Public health benefits of using more recycled water

Expanding the use of recycled water would reduce water and energy use, cut greenhouse gas emissions and benefit public health in California -- which is in the midst of a severe drought -- and around the world. [More]
Omalizumab drug can be better targeted to treat people with severe asthma

Omalizumab drug can be better targeted to treat people with severe asthma

Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS). [More]
Five centres awarded status of NHS Innovation Test Beds

Five centres awarded status of NHS Innovation Test Beds

NHS England has announced the five centres that have been awarded the status of Innovation Test Beds in which new approaches to healthcare provision will be assessed and adopted and two centres for the adoption of the Internet of Things (IoT) in healthcare. [More]
Diet rich in fiber may reduce risk of developing lung disease

Diet rich in fiber may reduce risk of developing lung disease

A diet rich in fiber may not only protect against diabetes and heart disease, it may reduce the risk of developing lung disease, according to new research published online, ahead of print in the Annals of the American Thoracic Society. [More]
Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone (O3) face an increased risk of dying from respiratory and cardiovascular diseases, according to the study "Long-Term Ozone Exposure and Mortality in a Large Prospective Study" published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
UA researchers find genetic mutations associated with respiratory disease

UA researchers find genetic mutations associated with respiratory disease

Asthma affects more than 278 million people worldwide and can lead to serious consequences later in life. While current approved therapies address symptoms, they do not halt disease progression. [More]
Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients who are exposed to higher daily levels of ozone are more likely to develop acute respiratory disease syndrome (ARDS), according to a new study published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Study reveals effects of plain packaging on tobacco products among Australian Indigenous people

Study reveals effects of plain packaging on tobacco products among Australian Indigenous people

Following the introduction of plain packaging on tobacco products in 2012, Australian Aboriginal and Torres Strait Islander people were 12 per cent less likely to think certain tobacco brands were less harmful than others, a new study found. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Music therapy in conjunction with standard rehabilitation benefits COPD patients

Music therapy in conjunction with standard rehabilitation benefits COPD patients

Patients with Chronic Obstructive Pulmonary Disease (COPD) and other chronic respiratory disorders who received music therapy in conjunction with standard rehabilitation saw an improvement in symptoms, psychological well-being and quality of life compared to patients receiving rehabilitation alone, according to a new study by researchers at The Louis Armstrong Center of Music and Medicine at Mount Sinai Beth Israel (MSBI). [More]
ATS commends President Obama for release of National Action Plan to combat TB

ATS commends President Obama for release of National Action Plan to combat TB

The American Thoracic Society applauds President Barack Obama and the Administration for the release of the National Action Plan to Combat Drug Resistant Tuberculosis (TB) today. [More]
Advertisement